epcoritamab
1 product
12 abstracts
Abstract
Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T).Org: Huntsman Cancer Institute/University of Utah, Washington University in St. Louis Department of Genetics, Division of Hematology, Mayo Clinic Florida,
Abstract
Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Org: Universitair Ziekenhuis Gent, Health Research Institute IIS-FJD, Lymphoma Service, Memorial Sloan Kettering Cancer Center,
Abstract
Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2.Org: Department of Internal Medicine – Hematology, Assistance Publique – Hôpitaux de Marseille (AP-HM), University Hospitals Plymouth NHS Trust, Clinical Hematology Department, On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC,
Abstract
EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma.Org: Manchester Cancer Research Centre, Sir Peter MacCallum Cancer Centre Melbourne, University of Modena and Reggio Emilia,
Abstract
Prevalence of adverse events following bispecific antibody therapy in non-Hodgkin lymphoma: A meta-analysis.Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Mayo Clinic, Mayo Clinic Arizona, Phoenix, AZ, Mayo Clinic Scottsdale,
Abstract
Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.Org: Lehigh Valley Health Network, University of Oklahoma, Stephenson Cancer Center, H. Lee Moffitt Cancer Center at Memorial Healthcare System, Stony Brook University Medical Center,
Abstract
Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).Org: Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Sir Charles Gairdner Hospital and the University of Western Australia, The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester,
Abstract
EPCORE NHL‑1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.Org: Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland,
Abstract
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.Org: Dana-Farber Cancer Institute, Institut Català D'Oncologia, Leiden University Medical Center, Rigshospitalet, Copenhagen University Hospital, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.Org: Lymphoma Service, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Vejle Hospital, Universitair Ziekenhuis Gent, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.Org: University of Michigan Comprehensive Cancer Center, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, MSC National Research Institute of Oncology, Kraków, Poland, Sir Charles Gairdner Hospital,
Abstract
Practice efficiency of treatment with epcoritamab versus glofitamab in relapsed/refractory diffuse large B-cell lymphoma.Org: Xcenda, LLC, Carrollton, TX, Alkemi LLC, Manchester Center, VT, AbbVie Inc., North Chicago, IL,
Product
Epcoritamab